Matches in Wikidata for { <http://www.wikidata.org/entity/Q37638139> ?p ?o ?g. }
- Q37638139 description "article científic" @default.
- Q37638139 description "article scientifique" @default.
- Q37638139 description "articolo scientifico" @default.
- Q37638139 description "artigo científico" @default.
- Q37638139 description "artículu científicu espublizáu en 2014" @default.
- Q37638139 description "bilimsel makale" @default.
- Q37638139 description "scientific article published on 15 January 2014" @default.
- Q37638139 description "vedecký článok" @default.
- Q37638139 description "vetenskaplig artikel" @default.
- Q37638139 description "videnskabelig artikel" @default.
- Q37638139 description "vědecký článek" @default.
- Q37638139 description "wetenschappelijk artikel" @default.
- Q37638139 description "wissenschaftlicher Artikel" @default.
- Q37638139 description "наукова стаття, опублікована в січні 2014" @default.
- Q37638139 description "научни чланак" @default.
- Q37638139 description "مقالة علمية نشرت في 15 يناير 2014" @default.
- Q37638139 name "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 name "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 name "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 type Item @default.
- Q37638139 label "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 label "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 label "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 prefLabel "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 prefLabel "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 prefLabel "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 P1433 Q37638139-FE5301F8-4D84-465E-B38E-A7FA5F7A3078 @default.
- Q37638139 P1476 Q37638139-1DDD68C3-14C9-4B2B-B138-7A6F12DA9B27 @default.
- Q37638139 P2093 Q37638139-136C77AA-4DA5-4B52-84E3-A753CE36CD3A @default.
- Q37638139 P2093 Q37638139-3F4B5FF7-EF46-4A3E-AC74-A177D8F2AF31 @default.
- Q37638139 P2093 Q37638139-546CC14A-FF48-4B93-9205-DBC6127C1AF2 @default.
- Q37638139 P2093 Q37638139-61536995-E786-4084-9476-7405706A4505 @default.
- Q37638139 P2093 Q37638139-6E201B16-2740-46DD-AFB8-F9CCD50599F8 @default.
- Q37638139 P2093 Q37638139-82438B8A-A68A-4286-AFAD-B24A6764B3EC @default.
- Q37638139 P2093 Q37638139-848EDC1B-1AD0-4DA6-88BF-E7721862E82F @default.
- Q37638139 P2093 Q37638139-97046000-375A-406A-ADEA-517B2F79B54E @default.
- Q37638139 P2093 Q37638139-BB2E9559-23E5-448E-A7EE-47C4DCD2C8C9 @default.
- Q37638139 P2093 Q37638139-BE864A89-8193-44AA-BFB9-F10625FC9744 @default.
- Q37638139 P2093 Q37638139-CCDA831D-94E2-4774-B75C-0656FA0097CA @default.
- Q37638139 P2093 Q37638139-D8F56BC4-7E5A-4B1E-88CD-A11B8C569E06 @default.
- Q37638139 P2093 Q37638139-DFCEF80F-B7C3-44E0-B191-AFDE92FCCF4C @default.
- Q37638139 P2093 Q37638139-EC52A76A-189A-4687-9C7A-5F8BDBFF4484 @default.
- Q37638139 P2093 Q37638139-FC8BC862-61EA-43EE-BC24-C86DA3FB0718 @default.
- Q37638139 P2860 Q37638139-01DDD91A-6537-4177-9D19-FAF4B464F8B5 @default.
- Q37638139 P2860 Q37638139-1F2A54A8-B024-491A-A1C0-23E089943226 @default.
- Q37638139 P2860 Q37638139-38CE2629-7614-4EF7-A9CF-A116A94D5EEA @default.
- Q37638139 P2860 Q37638139-40CE7E41-301D-4523-9803-3D94EA2D71C1 @default.
- Q37638139 P2860 Q37638139-43352265-3C04-4B70-9CEE-2D3F9F586118 @default.
- Q37638139 P2860 Q37638139-45498523-0BF3-46FD-836D-A31C6861D44F @default.
- Q37638139 P2860 Q37638139-4FA326A8-A640-4ECC-A09C-E7C3304C1874 @default.
- Q37638139 P2860 Q37638139-51171F7E-8617-4BBF-8D53-E309E06C3AC7 @default.
- Q37638139 P2860 Q37638139-554D463F-1993-4CAE-8495-9D3156221FE5 @default.
- Q37638139 P2860 Q37638139-62BDF522-E02A-406A-AAF5-E7A084A63A42 @default.
- Q37638139 P2860 Q37638139-66EA369F-9788-45C9-B3B0-8CF3AC873089 @default.
- Q37638139 P2860 Q37638139-696AB119-4ECC-4F8F-A8B7-6B3447E898C4 @default.
- Q37638139 P2860 Q37638139-72C55321-4B37-42EC-8A8C-D1C3C89FF220 @default.
- Q37638139 P2860 Q37638139-95FAFAB4-C835-407F-B745-2A8806F2B6ED @default.
- Q37638139 P2860 Q37638139-966E28D7-0859-4B35-8B0D-FAB511E42CF0 @default.
- Q37638139 P2860 Q37638139-A188D29B-B218-45AB-8B65-2141AD275F05 @default.
- Q37638139 P2860 Q37638139-B6BB297D-C3C0-4CCA-8383-89D669AFB46F @default.
- Q37638139 P2860 Q37638139-B8F36E03-31B5-43CB-A35D-C92E5600B56C @default.
- Q37638139 P2860 Q37638139-DDEA39DD-D627-4249-AF85-CB18C1643D22 @default.
- Q37638139 P2860 Q37638139-DF3FAB33-AA07-4B04-96C4-160CE9918963 @default.
- Q37638139 P2860 Q37638139-EC2847C3-E2D2-484E-8FC2-39729A988BF9 @default.
- Q37638139 P2860 Q37638139-EF88F697-1066-4499-A406-CAD0669B1F95 @default.
- Q37638139 P2860 Q37638139-F0F0DA18-68C5-49FA-BBC5-17C9DD01ADD7 @default.
- Q37638139 P2860 Q37638139-F668AD19-87BD-41A6-8B30-5B92E71176CE @default.
- Q37638139 P2860 Q37638139-FCEF20E0-C3E8-45A3-B6F5-3F24B68AAE86 @default.
- Q37638139 P2860 Q37638139-FDB355B6-00B3-4A48-A61E-0296D6DC033A @default.
- Q37638139 P304 Q37638139-ABDD7526-5318-4929-8971-E111899D6B75 @default.
- Q37638139 P31 Q37638139-4090B7B9-B2FF-49D0-ACFE-CF6FB1887172 @default.
- Q37638139 P356 Q37638139-772A0BD9-75B7-42CE-A223-E7BD71250E9D @default.
- Q37638139 P433 Q37638139-15550126-D565-4AC4-95A0-9F6ED33E6E2F @default.
- Q37638139 P478 Q37638139-22FA1E5D-7B59-4581-BAEC-C374491316F2 @default.
- Q37638139 P50 Q37638139-2FE0DF72-8A8A-4C5C-8BF7-7F5435471872 @default.
- Q37638139 P50 Q37638139-4992423F-28B6-43FC-B991-A79AFC765D2F @default.
- Q37638139 P50 Q37638139-565737B7-3BD2-4960-B363-F3AD286532D8 @default.
- Q37638139 P50 Q37638139-C21876E9-A3AB-4C66-AA0C-73BA3C581D61 @default.
- Q37638139 P50 Q37638139-EAC4FFE4-16F0-4A55-BB03-66F7EB84389D @default.
- Q37638139 P577 Q37638139-3C1B1B39-D475-4DB6-9A6B-C3A272B5C296 @default.
- Q37638139 P698 Q37638139-4CBCB55F-6CE9-4101-848E-4F5D37C29422 @default.
- Q37638139 P921 Q37638139-64267D91-D59D-4B89-93A0-557A9B45369B @default.
- Q37638139 P921 Q37638139-7DE162D7-41E7-4596-B849-37C2534C1C84 @default.
- Q37638139 P921 Q37638139-B091DAEA-59AD-422C-B53D-D8720739E24E @default.
- Q37638139 P932 Q37638139-4F4C5C10-E532-470D-80DC-234B82668137 @default.
- Q37638139 P356 S1470-2045(13)70596-5 @default.
- Q37638139 P698 24439931 @default.
- Q37638139 P1433 Q13747613 @default.
- Q37638139 P1476 "Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial" @default.
- Q37638139 P2093 "Ariel Lopez Chavez" @default.
- Q37638139 P2093 "Arlene Berman" @default.
- Q37638139 P2093 "Arun Rajan" @default.
- Q37638139 P2093 "Barbara Scepura" @default.
- Q37638139 P2093 "Corey A Carter" @default.
- Q37638139 P2093 "Gregory J Riely" @default.
- Q37638139 P2093 "Helen X Chen" @default.
- Q37638139 P2093 "Isabella Bergagnini" @default.
- Q37638139 P2093 "Liang Cao" @default.
- Q37638139 P2093 "Lindsey B Rosen" @default.
- Q37638139 P2093 "Min-Jung Lee" @default.